Kiley Juergens Wealth Management LLC Buys Shares of 5,735 Abbott Laboratories $ABT

Kiley Juergens Wealth Management LLC bought a new stake in shares of Abbott Laboratories (NYSE:ABT) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,735 shares of the healthcare product maker’s stock, valued at approximately $589,000.

Other hedge funds also recently modified their holdings of the company. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at $25,000. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories during the 4th quarter worth $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT stock opened at $95.80 on Wednesday. The firm has a 50 day moving average of $89.10 and a 200-day moving average of $103.74. The firm has a market capitalization of $166.86 billion, a P/E ratio of 26.83, a price-to-earnings-growth ratio of 1.65 and a beta of 0.61. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the prior year, the company posted $1.09 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ABT shares. Leerink Partners lowered their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Weiss Ratings downgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 16th. Barclays lowered their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research report on Monday, April 20th. Sanford C. Bernstein dropped their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, TD Cowen cut their price objective on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.42.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.